The Maryland Health Care Commission has created a consumer education campaign that puts the costs of common health care procedures on a place where people might see them – T-shirts.
Desperate for help in finding a lifesaving drug for a fatal genetic disease, families banded together to fund early research and then worked with drug companies on clinical trials and marketing. Yet, this small patient advocacy group is stunned by pharma’s pricing.
At least 11 states are going to try to tax opioids despite pushback from pharmaceutical companies.
Rep. Chris Collins talked one time too many, according to federal prosecutors who on Wednesday charged him with violating insider trading laws.
Grants by top pharma group to lightly regulated, politically active nonprofits dwarf its conventional campaign spending.
Several major drugmakers vow to contain drug prices, but similar pledges since the 1990s have not had much impact.
The Trump administration issued the final rule on association health plans, which supporters say will make coverage more affordable for some employees but led others to warn about “junk insurance.”
Promises to control pharma prices threaten profits for Switzerland-based Novartis, which sells some of the costliest drugs in the world.
Companies pushed proton machines and counted on advertising, doctors and insurers to ensure a steady business treating cancer. But the dollars haven’t flowed in as expected.
Denmark-based drugmaker Novo Nordisk has invested more in lobbying and doubled political donations since 2015.
The state’s ambitious payment overhaul has begun to demonstrate savings and a change in culture, say new reports.
In Louisiana, the wining and dining of lawmakers by scores of pharma lobbyists proves a valuable lesson on how to win statehouse votes and influence profits.
Last year, the pharma industry’ biggest trade group raised millions to change the conversation about drug pricing.
The Affordable Care Act has increased the number of people with insurance, but shopping around for plans puts a burden on patients, especially this year.
Months of reporting and rich hospital data portray life in the worst asthma hot spot in one of the worst asthma cities: Baltimore. The medical system knows how to help. But there’s no money in it.
Es esencial que conozca sus opciones en base a los ingresos y al tamaño de su familia. Aquí, algunas respuestas clave para entender el mercado de seguros.
This year, more than ever, it is important to know your options.
Drug companies are in the midst of a glossy publicity campaign to stop attempts to control rising pharma costs. But the devil is in the details.
Any momentum to address prescription drug costs has been lost amid rancorous debates over replacing Obamacare and stalled by roadblocks erected via lobbying and industry cash.
Most acquisitions by hospitals of physician practices are too small to trigger antitrust attention, study says. But a buying spree of “onesies and twosies” doctor practices has driven competition down and prices up.